Dresden 2014 – wissenschaftliches Programm
Bereiche | Tage | Auswahl | Suche | Aktualisierungen | Downloads | Hilfe
BP: Fachverband Biologische Physik
BP 42: Biotechnology and bioengineering
BP 42.6: Vortrag
Freitag, 4. April 2014, 11:00–11:15, HÜL 386
Heart-on-a-chip - Design, Fabrication, and Characterization of a Microphysiological Platform for Drug Screening in Cardiac Tissue — •Peter Loskill1, Anurag Mathur1, Zhen Ma1, Micaela Finnegan1, Natalie C. Marks1, SoonGweon Hong1, Bruce R. Conklin2, Luke P. Lee1, and Kevin E. Healy1 — 1Department of Bioengineering, UC Berkeley, Berkeley, United States — 2Gladstone Institute of Cardiovascular Disease, San Francisco, United States
Drug discovery and development to date has relied on animal models, which are useful, but fail to resemble human physiology. The discovery of human induced pluripotent stem (iPS) cells has led to the emergence of a new paradigm of drug screening using human disease-specific organ-like cultures in a dish. One promising approach to produce these organ-like structures is the use of microfluidic devices, which can simulate 3D tissue structure and function with microphysiological features. Using microfabrication techniques we have developed a 3D microphysiological platform that mimics human cardiac tissue and is amenable to drug screening. The microfluidic 3D culture platform consists of three functional components: endothelial like barriers that are 2 µm wide; 30 µm wide capillary like media channels; and 100-200 µm wide cell culture channels. The platform is able to create a functional cardiac microtissue with physiological beat rates (60-80 beats/min) and with viability for multiple weeks. Assessing the physiological response to various cardiac drugs validated function of the cardiac microtissue. The microphysiological platform is extremely versatile and can be used for drug toxicity screening and therapeutic applications.